Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07832214
Active, not recruiting Not applicable

Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient.

NCT07832214 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Not applicable
Started
2026-07-01
Last updated
2026-09-21

Condition(s) studied

Cough SuppressionThyroidectomy

Investigational drug(s) / intervention(s)

· Dex-Lido solution: Dexmedetomidine 100 μg/mL (concentration) was diluted with 2% lidocaine to achieve final concentration of dexmedetomidine 1 μg/kg in 5 mL total volume· Lido solution: 2% lidocaine, 5 mL· Control solution: 0.9% normal saline, 5 mL

· Dex-Lido solution: Dexmedetomidine 100 μg/mL (concentration) was diluted with 2% lidocaine to achieve final concentration of dexmedetomidine 1 μg/kg in 5 mL total volume: * Dex-Lido solution: Dexmedetomidine 100 μg/mL (concentration) was diluted with 2% lidocaine to achieve final concentration of dexmedetomidine 1 μg/kg in 5 mL total volume * Lido solution: 2% lidocaine, 5 mL * Control solution: 0.9% normal saline, 5 mL All solutions were prepared under aseptic conditions immediately before use and loaded into identical 5 mL syringes attached to a mucosal atomization device (MADgic™, Teleflex Medical) capable of delivering fine-particle spray.

· Lido solution: 2% lidocaine, 5 mL: · Lido solution: 2% lidocaine, 5 mL All solutions were prepared under aseptic conditions immediately before use and loaded into identical 5 mL syringes attached to a mucosal atomization device (MADgic™, Teleflex Medical) capable of delivering fine-particle spray.

· Control solution: 0.9% normal saline, 5 mL: · Control solution: 0.9% normal saline, 5 mL All solutions were prepared under aseptic conditions immediately before use and loaded into identical 5 mL syringes attached to a mucosal atomization device (MADgic™, Teleflex Medical) capable of delivering fine-particle spray.

Study summary

Study Hypothesis: The combination of dexmedetomidine and lidocaine administered as laryngopharyngeal topical spray provides superior suppression of extubation cough reflex compared to lidocaine alone or placebo, without compromising recovery or increasing adverse events

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Female patients aged 18-65 years * American Society of Anesthesiologists (ASA) physical status I-II * Scheduled for elective thyroidectomy under general anesthesia with endotracheal intubation * Provided written informed consent Exclusion Criteria: * Known allergy or contraindication to dexmedetomidine, lidocaine, or study medications * Pre-existing cough or respiratory tract infection within 2 weeks * History of chronic cough or reactive airway disease (asthma, COPD) * Significant cardiovascular disease (arrhythmias, uncontrolled hypertension, heart failure) * Hepatic or renal dysfunction (liver enzymes \>2× upper normal limit, creatinine \>1.5 mg/dL) * Pregnancy or breastfeeding * Anticipated difficult airway (Mallampati class III-IV, limited neck extension) * Preoperative use of antitussive medications or opioids * Body mass index \>35 kg/m² * Emergency surgery * Participation in another interventional trial within 30 days

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine, Sohag University Sohag Egypt

More Sohag University trials in Egypt

This Study Aims to Characterize and Compare Patients of Adult-onset RA With Patients of Elderly-onset RA Based on the Clinical Manifestations, Disease Activity, Severity Parameters, and Therapeutic Features Active, not recruiting
Risk Stratification and Prognostic Value of Right Ventricular Dysfunction Screening Using Transthoracic Echocardiography in Acute Pulmonary Embolism Recruiting
Dose for Reversal of Heparin After Cardiopulmonary Bypass Recruiting
Fixation of Medial Malleolar Fractures . Active, not recruiting
Recurrence of H Pylori : Incidence and Influential Factors. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07832214 on ClinicalTrials.gov ↗ ← All trials in Egypt